For managed care organizations and health systems, the recommendations strongly advocated highly selective use of NGS. Routine, nonselective NGS for all sarcoma patients is not justified. Instead, ...

A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...

(Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the formation of a newly ...

Co-Diagnostics (CODX) announced the formation of a newly organized, artificial intelligence business unit, led by Chief Technology & AI Officer ...

DNA polymerases lie at the heart of diagnostic techniques like polymerase chain reaction (PCR), enabling early detection of ...

Closing rural diagnostic gap, HealthTrackRx delivers next-morning PCR test results nationwide to improve infection diagnosis and treatment.

World's largest TB prize illuminates Indian Molbio’s tech innovation reaching the unreached. By SHOBHA SHUKLA and BOBBY RAMAKANT ...

Join Dwight Egan, CEO of Co-Dx, for an update on the Company's growth initiatives, including its recently announced definitive agreement with Arabian Eagle in the Kingdom of Saudi Arabia to form ...

Studies showed that the assay demonstrated a 94.90% sensitivity in polymerase chain reaction-confirmed positive samples.

Background Stillbirth rates remain unacceptably high in low- and middle-income countries (LMICs). Understanding the causes of ...

Co-Dx will equip the JV with an exclusive licence to utilise, produce, and market the licensed intellectual property.

Co-Diagnostics, Inc. (NASDAQ:CODX) announced on Monday that it has entered into a joint venture agreement with the Kingdom of ...